Literature DB >> 11513810

Interleukin-2-induced small unilamellar vesicle coalescence.

L T Boni1, M M Batenjany, M E Neville, Y Guo, L Xu, F Wu, J T Mason, R J Robb, M C Popescu.   

Abstract

Recombinant human interleukin-2 (rhIL-2) was incorporated in liposomes for potential therapeutic applications using a novel process. In this process, rhIL-2 caused the formation of large, unique multilamellar vesicles (MLVs) from small unilamellar vesicles (SUVs) of dimyristoylphosphatidylcholine (DMPC). Vesicle coalescence occurred most rapidly at 19 degrees C, between the pre- and main phase transition temperatures of DMPC, and showed a dependence upon pH (pH <5.5), ionic strength (>50 mM) and the initial size of the unilamellar vesicles (<or=25 nm). Intermediates (partially coalesced vesicles) within the forming multilamellar structures were identified by freeze-fracture electron microscopy and their presence was corroborated by differential scanning calorimetry. Several distinct steps were identified in the coalescence process. In the initial step, rhIL-2 rapidly bound to the DMPC SUVs. This was followed by a pH-dependent conformational change in the protein, as evidenced by an increase in tryptophan fluorescence intensity. The SUVs then aggregated in large clusters that eventually annealed to form closed MLVs. In this process over 90% of the rhIL-2 was bound to and incorporated within the multilamellar structures.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11513810     DOI: 10.1016/s0005-2736(01)00377-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  A novel proteoliposomal vaccine elicits potent antitumor immunity in mice.

Authors:  Mircea C Popescu; Richard J Robb; Michael M Batenjany; Lawrence T Boni; Mary E Neville; Robin W Pennington; Sattva S Neelapu; Larry W Kwak
Journal:  Blood       Date:  2007-03-09       Impact factor: 22.113

2.  A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma.

Authors:  Sattva S Neelapu; Barry L Gause; Linda Harvey; Seung-Tae Lee; Andrea Robin Frye; Jessie Horton; Richard J Robb; Mircea C Popescu; Larry W Kwak
Journal:  Blood       Date:  2007-03-05       Impact factor: 22.113

3.  MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.

Authors:  P Mukherjee; A R Ginardi; C S Madsen; T L Tinder; F Jacobs; J Parker; B Agrawal; B M Longenecker; S J Gendler
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

4.  Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.

Authors:  Manuel F Fernandez; Guilin Qiao; Kiara Tulla; Bellur S Prabhakar; Ajay V Maker
Journal:  J Surg Res       Date:  2021-02-22       Impact factor: 2.417

Review 5.  Smart Lipid-Based Nanosystems for Therapeutic Immune Induction against Cancers: Perspectives and Outlooks.

Authors:  Seth-Frerich Fobian; Ziyun Cheng; Timo L M Ten Hagen
Journal:  Pharmaceutics       Date:  2021-12-23       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.